Initial Assessment and Confirmation

Measure serum calcium, phosphate, and parathyroid hormone (PTH) levels to evaluate for metabolic bone disorders, as recommended by the Kidney International guidelines 1

Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a common cause of elevated ALP, according to the American Journal of Kidney Diseases and Kidney International guidelines 2, 1

Serum calcium and phosphate levels should be measured to evaluate bone metabolism, as recommended by the Kidney International guidelines 1
25-hydroxyvitamin D level should be measured to evaluate for vitamin D deficiency, as recommended by the Kidney International and Nature Reviews Nephrology guidelines 1, 3
Parathyroid hormone (PTH) level should be measured to evaluate for hyperparathyroidism, as recommended by the Kidney International guidelines 1
Bone-specific alkaline phosphatase (B-ALP) should be measured to evaluate bone turnover, as recommended by the Kidney International guidelines 1, 4

Vitamin D deficiency should be treated with vitamin D supplements, as recommended by the Nature Reviews Nephrology guidelines 3
Hypophosphatemia should be treated with oral phosphate supplements, as recommended by the Nature Reviews Nephrology guidelines 3
Hyperparathyroidism should be treated according to the underlying cause, as recommended by the Kidney International guidelines 1

Serum calcium, phosphate, and PTH levels should be monitored regularly based on CKD stage, as recommended by the Kidney International guidelines 1
Alkaline phosphatase activity should be monitored every 12 months in CKD G4-G5D patients, or more frequently with elevated PTH, as recommended by the Kidney International guidelines 1

Important Considerations

In CKD patients, bone-specific alkaline phosphatase may be more reliable than PTH for assessing bone turnover, as recommended by the Kidney International guidelines 4

The American College of Physicians recommends determining if the elevated ALP is bone-specific by checking bone-specific alkaline phosphatase (B-ALP) isoenzymes, which can help confirm the bone origin of the elevation 5
Assessing for clinical symptoms such as bone pain, which together with elevated ALP significantly increases the likelihood of bone metastases (up to approximately 10%) 6, 7
Considering time of day when interpreting ALP levels, as bone markers vary according to circadian rhythms with levels generally peaking in the morning 5, 8

The National Comprehensive Cancer Network recommends bone scan as the primary recommended imaging modality for elevated ALP of suspected bone origin 6, 7
For patients with known malignancy (especially renal, breast, or prostate cancer), bone scan is particularly indicated when ALP is elevated 6, 7, 5
Considering additional imaging based on bone scan results, such as targeted radiographs, MRI, or CT imaging 5, 8, 6

Osteomalacia and hyperparathyroidism are non-malignant bone disorders that can cause elevated ALP 9
Medication-induced changes in bone turnover can also cause elevated ALP 5, 8

For malignancy, referring to appropriate oncology specialists and considering bone-targeted agents (bisphosphonates or denosumab) to prevent skeletal-related events 6, 7, 5, 8
For metabolic bone disease, ensuring adequate calcium and vitamin D supplementation and addressing underlying causes such as renal dysfunction 9, 6

Periodic monitoring of ALP levels to assess response to treatment 6, 7
Continuing monitoring ALP as part of routine laboratory evaluation for patients with treated malignancies 6, 7
Considering alternative diagnoses or treatment resistance if ALP remains elevated despite initial treatment 5, 8

The Kidney International recommends bone-specific alkaline phosphatase (B-ALP) as a superior marker to total alkaline phosphatase for diagnosing and monitoring bone disease, particularly in chronic kidney disease-mineral bone disorder (CKD-MBD) 10

The Kidney International suggests measuring B-ALP in adults with CKD stages 3a-5D to evaluate bone turnover, as it is more reliable than PTH alone for assessing bone disease 10
The Alimentary Pharmacology and Therapeutics recommends measuring B-ALP when total ALP is elevated and the source (bone vs. liver) needs clarification 11
The Cancer Treatment Reviews indicates that B-ALP is useful in patients with known malignancy (breast, prostate, renal cell carcinoma) where bone metastases are suspected 12, 13
The Nature Reviews Nephrology suggests monitoring total serum ALP in children and bone-specific ALP in adults with X-linked hypophosphatemia (XLH) every 6 months 14

The Kidney International recommends measuring B-ALP every 12 months in CKD G4-G5D, or more frequently if PTH is elevated 10
The Nature Reviews Nephrology and Kidney International suggest measuring B-ALP alongside serum calcium, phosphate, PTH, and 25(OH) vitamin D 10, 14
The Cancer Treatment Reviews recommends using B-ALP to assess response to bone-targeted agents (bisphosphonates, denosumab) in cancer patients 12, 13
The American Journal of Kidney Diseases notes that in CKD, B-ALP may be more reliable than PTH due to accumulation of inactive PTH fragments that cross-react with intact PTH assays 15

The elevation of ALP in CKD without biliary disease is predominantly driven by bone-specific alkaline phosphatase (B-ALP) secondary to secondary hyperparathyroidism and altered bone metabolism, as recommended by the American Journal of Kidney Diseases 16, 17
Secondary hyperparathyroidism develops early in CKD, typically when GFR falls below 60 mL/min/1.73 m², Stage 3, and stimulates increased bone turnover, releasing bone-specific ALP into circulation, according to the American Journal of Kidney Diseases 16, 18

Measure bone-specific alkaline phosphatase directly rather than relying on total ALP alone, as this provides superior diagnostic accuracy for bone disease in CKD, as suggested by Kidney International 17

Elevated B-ALP also predicts fracture risk in dialysis patients, with a hazard ratio of 1.04-1.21, as reported by Kidney International 17

Treatment decisions should be based on serial measurements of phosphate, calcium, and PTH considered together, not on ALP or any single laboratory value in isolation, as recommended by the Annals of Internal Medicine 19, 20, 21
In CKD G3a-G5D, lower elevated phosphate levels toward the normal range, with a Grade 2C recommendation from the Annals of Internal Medicine 19, 20
Avoid hypercalcemia in adult CKD patients, with a Grade 2C recommendation from the Annals of Internal Medicine 19, 20
Consider bone biopsy when PTH levels are between 100-500 pg/mL and the patient develops unexplained hypercalcemia, bone pain, or increase in bone alkaline phosphatase activity, as suggested by the American Journal of Kidney Diseases 16